NexImmune, Inc. financial data

Symbol
NEXI on OTC
Industry
Pharmaceutical Preparations
Location
9119 Gaither Road, Gaithersburg, MD
State of incorporation
Delaware
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2024 - Aug 7, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 120 % -70.4%
Debt-to-equity 147 % +417%
Return On Equity -542 % -235%
Return On Assets -217 % -72.3%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 1.39M shares -94.7%
Common Stock, Shares, Outstanding 1.39M shares -94.7%
Entity Public Float 5.8M USD -79.8%
Common Stock, Value, Issued 139 USD -94.7%
Weighted Average Number of Shares Outstanding, Basic 1.38M shares +32.3%
Weighted Average Number of Shares Outstanding, Diluted 1.38M shares +32.3%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 0 USD
Research and Development Expense 9.67M USD -73%
General and Administrative Expense 10.5M USD -24.2%
Operating Income (Loss) -21.6M USD +56.5%
Nonoperating Income (Expense) 1.01M USD +5.63%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -20.6M USD +57.7%
Earnings Per Share, Basic -18.6 USD/shares +76.8%
Earnings Per Share, Diluted -18.6 USD/shares +76.8%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 2.42M USD -85.1%
Marketable Securities, Current 0 USD -100%
Cash, Cash Equivalents, and Short-term Investments 45.9M USD
Other Assets, Current 40.6K USD -86.7%
Assets, Current 3.13M USD -83.1%
Property, Plant and Equipment, Net 1.11M USD -72.1%
Operating Lease, Right-of-Use Asset 0 USD -100%
Other Assets, Noncurrent 1.63M USD +442%
Assets 5.86M USD -75%
Accounts Payable, Current 1.28M USD +120%
Employee-related Liabilities, Current 351K USD -85.3%
Accrued Liabilities, Current 3.46M USD -32.8%
Liabilities, Current 4.74M USD -24.4%
Operating Lease, Liability, Noncurrent 0 USD -100%
Liabilities 4.94M USD -23.7%
Accumulated Other Comprehensive Income (Loss), Net of Tax 0 USD -100%
Retained Earnings (Accumulated Deficit) -228M USD -9.94%
Stockholders' Equity Attributable to Parent 696K USD -95.9%
Liabilities and Equity 5.86M USD -75%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -2.42M USD +80.3%
Net Cash Provided by (Used in) Financing Activities 3.14M USD
Net Cash Provided by (Used in) Investing Activities 523K USD
Common Stock, Shares Authorized 250M shares 0%
Common Stock, Shares, Issued 1.39M shares -94.7%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 1.25M USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 2.44M USD -85%
Interest Paid, Excluding Capitalized Interest, Operating Activities 0 USD -100%
Deferred Tax Assets, Valuation Allowance 43.8M USD +12.8%
Deferred Tax Assets, Gross 44M USD +11.9%
Operating Lease, Liability 68.8K USD -93.3%
Payments to Acquire Property, Plant, and Equipment 0 USD -100%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -32.3M USD +48.3%
Lessee, Operating Lease, Liability, to be Paid 68.9K USD -93.7%
Property, Plant and Equipment, Gross 2.67M USD -65.5%
Operating Lease, Liability, Current 0 USD -100%
Lessee, Operating Lease, Liability, to be Paid, Year Two 0 USD -100%
Lessee, Operating Lease, Liability, to be Paid, Year One 68.9K USD -88.9%
Operating Lease, Weighted Average Discount Rate, Percent 0.07 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 89K USD +41%
Lessee, Operating Lease, Liability, to be Paid, Year Three 0 USD
Deferred Tax Assets, Operating Loss Carryforwards 32.5M USD +14.1%
Preferred Stock, Shares Issued 1 shares
Preferred Stock, Shares Authorized 0 shares -100%
Unrecognized Tax Benefits 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 0 USD
Operating Lease, Payments 133K USD
Additional Paid in Capital 229M USD +1.92%
Preferred Stock, Shares Outstanding 1 shares
Depreciation, Depletion and Amortization 115K USD -56.4%
Deferred Tax Assets, Net of Valuation Allowance 148K USD -67.8%
Share-based Payment Arrangement, Expense 2.35M USD -50.5%
Interest Expense 0 USD -100%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares